- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 233/76 - Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
Patent holdings for IPC class C07D 233/76
Total number of patents in this class: 87
10-year publication summary
|
6
|
2
|
8
|
3
|
8
|
3
|
5
|
3
|
6
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Autifony Therapeutics Limited | 49 |
5 |
| Evonik Operations GmbH | 4160 |
5 |
| Buck Institute for Research on Aging | 129 |
4 |
| King Faisal University | 921 |
4 |
| Oxiscience Wa, LLC | 10 |
4 |
| Bristol-myers Squibb Company | 4848 |
3 |
| The Regents of the University of California | 20230 |
2 |
| AstraZeneca AB | 2857 |
2 |
| Evonik Degussa GmbH | 1466 |
2 |
| Elanco US Inc. | 734 |
2 |
| The Glad Products Company | 504 |
2 |
| Monash University | 719 |
2 |
| Schering Corporation | 418 |
2 |
| Swiss Tropical and Public Health Institute | 8 |
2 |
| F. Hoffmann-La Roche AG | 7932 |
1 |
| Allergan, Inc. | 2315 |
1 |
| Bayer AG | 3384 |
1 |
| Huawei Technologies Co., Ltd. | 115187 |
1 |
| Sumitomo Chemical Company, Limited | 9095 |
1 |
| DSM IP Assets B.V. | 5553 |
1 |
| Other owners | 40 |